TUB-040

NaPi2b-targeted antibody-drug conjugate · Tubulis GmbH

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TUB-040, covering 2026-03-03 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC [Phase 1, Phase 2]

See pricing